{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:01:01Z","timestamp":1791874861205,"version":"4.3.4"},"reference-count":152,"publisher":"Aging and Disease","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2025]]},"DOI":"10.14336\/ad.2025.0619","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T04:12:02Z","timestamp":1751861522000},"page":"0","source":"Crossref","is-referenced-by-count":8,"title":["Metabolic Dysregulation in Parkinson\u2019s Disease: Non-Oxidative Phosphorylation and Its Role in Brain Energy Metabolism"],"prefix":"10.14336","author":[{"given":"Marta","family":"Pokotylo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Br\u00fcggemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Prasuhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2025.0619-1","unstructured":"Dorsey ER, Elbaz A, Nichols E, Abbasi N, Abd-Allah F, Abdelalim A, et al (2018). Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 17:939-53."},{"key":"key-10.14336\/AD.2025.0619-2","doi-asserted-by":"crossref","unstructured":"Kalia LV, Lang AE (2015). Parkinson\u2019s disease. Lancet, 386:896-912.","DOI":"10.1016\/S0140-6736(14)61393-3"},{"key":"key-10.14336\/AD.2025.0619-3","unstructured":"Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt E-J, Laabs B-H, et al (2024). Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson\u2019s disease study. Brain, 147:2652-67."},{"key":"key-10.14336\/AD.2025.0619-4","doi-asserted-by":"crossref","unstructured":"Cook L, Verbrugge J, Schwantes-An T-H, Schulze J, Foroud T, Hall A, et al (2024). Parkinson\u2019s disease variant detection and disclosure: PD GENEration, a North American study. Brain, 147:2668-79.","DOI":"10.1093\/brain\/awae142"},{"key":"key-10.14336\/AD.2025.0619-5","doi-asserted-by":"crossref","unstructured":"Greenfield JG, Bosanquet FD (1953). THE BRAIN-STEM LESIONS IN PARKINSONISM. J Neurol Neurosurg Psychiatry, 16:213-26.","DOI":"10.1136\/jnnp.16.4.213"},{"key":"key-10.14336\/AD.2025.0619-6","doi-asserted-by":"crossref","unstructured":"Moradi Vastegani S, Nasrolahi A, Ghaderi S, Belali R, Rashno M, Farzaneh M, Khoshnam SE (2023). Mitochondrial Dysfunction and Parkinson\u2019s Disease: Pathogenesis and Therapeutic Strategies. Neurochem Res, 48:2285-308.","DOI":"10.1007\/s11064-023-03904-0"},{"key":"key-10.14336\/AD.2025.0619-7","doi-asserted-by":"crossref","unstructured":"Karbowski M, Neutzner A (2012). Neurodegeneration as a consequence of failed mitochondrial maintenance. Acta Neuropathol, 123:157-71.","DOI":"10.1007\/s00401-011-0921-0"},{"key":"key-10.14336\/AD.2025.0619-8","doi-asserted-by":"crossref","unstructured":"Henrich MT, Oertel WH, Surmeier DJ, Geibl FF. Mitochondrial dysfunction in Parkinson\u2019s disease - a key disease hallmark with therapeutic potential (2023). Mol Neurodegener, 18:83.","DOI":"10.1186\/s13024-023-00676-7"},{"key":"key-10.14336\/AD.2025.0619-9","doi-asserted-by":"crossref","unstructured":"Shim JH, Yoon SH, Kim K-H, Han JY, Ha J-Y, Hyun DH, et al (2011). The antioxidant Trolox helps recovery from the familial Parkinson\u2019s disease-specific mitochondrial deficits caused by PINK1- and DJ-1-deficiency in dopaminergic neuronal cells. Mitochondrion, 11:707-15.","DOI":"10.1016\/j.mito.2011.05.013"},{"key":"key-10.14336\/AD.2025.0619-10","doi-asserted-by":"crossref","unstructured":"M\u00fcft\u00fcoglu M, Elibol B, Dalm\u0131zrak \u00d6, Ercan A, Kulaks\u0131z G, \u00d6g\u00fcs H, et al (2004). Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord, 19:544-8.","DOI":"10.1002\/mds.10695"},{"key":"key-10.14336\/AD.2025.0619-11","doi-asserted-by":"crossref","unstructured":"B\u00fcttner S, Bitto A, Ring J, Augsten M, Zabrocki P, Eisenberg T, et al (2008). Functional Mitochondria Are Required for \u03b1-Synuclein Toxicity in Aging Yeast. J Biol Chem, 283:7554-60.","DOI":"10.1074\/jbc.M708477200"},{"key":"key-10.14336\/AD.2025.0619-12","doi-asserted-by":"crossref","unstructured":"Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, et al (2009). Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson\u2019s disease. Brain, 132:3285-97.","DOI":"10.1093\/brain\/awp293"},{"key":"key-10.14336\/AD.2025.0619-13","doi-asserted-by":"crossref","unstructured":"Rolfe DF, Brown GC (1997). Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev, 77:731-58.","DOI":"10.1152\/physrev.1997.77.3.731"},{"key":"key-10.14336\/AD.2025.0619-14","doi-asserted-by":"crossref","unstructured":"Blomqvist G, Seitz RJ, Sj\u00f6gren I, Halldin C, Stone\u2010Elander S, Widen L, et al (1994). Regional cerebral oxidative and total glucose consumption during rest and activation studied with positron emission tomography. Acta Physiol Scand, 151:29-43.","DOI":"10.1111\/j.1748-1716.1994.tb09718.x"},{"key":"key-10.14336\/AD.2025.0619-15","doi-asserted-by":"crossref","unstructured":"Harris JJ, Jolivet R, Attwell D (2012). Synaptic Energy Use and Supply. Neuron, 75:762-77.","DOI":"10.1016\/j.neuron.2012.08.019"},{"key":"key-10.14336\/AD.2025.0619-16","doi-asserted-by":"crossref","unstructured":"Hattori N, Tanaka M, Ozawa T, Mizuno Y (1991). Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in parkinson\u2019s disease. Ann Neurol, 30:563-71.","DOI":"10.1002\/ana.410300409"},{"key":"key-10.14336\/AD.2025.0619-17","doi-asserted-by":"crossref","unstructured":"Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, et al (1995). Low platelet mitochondrial complex I and complex II\/III activity in early untreated parkinson\u2019s disease. Ann Neurol, 37:714-22.","DOI":"10.1002\/ana.410370604"},{"key":"key-10.14336\/AD.2025.0619-18","doi-asserted-by":"crossref","unstructured":"Parker WD, Boyson SJ, Parks JK (1989). Abnormalities of the electron transport chain in idiopathic parkinson\u2019s disease. Ann Neurol, 26:719-23.","DOI":"10.1002\/ana.410260606"},{"key":"key-10.14336\/AD.2025.0619-19","doi-asserted-by":"crossref","unstructured":"Requejo-Aguilar R, Bola\u00f1os JP (2016). Mitochondrial control of cell bioenergetics in Parkinson\u2019s disease. Free Radic Biol Med, 100:123-37.","DOI":"10.1016\/j.freeradbiomed.2016.04.012"},{"key":"key-10.14336\/AD.2025.0619-20","doi-asserted-by":"crossref","unstructured":"K\u00f6nig A, Outeiro TF (2024). Diabetes and Parkinson\u2019s Disease: Understanding Shared Molecular Mechanisms. J Parkinsons Dis, 14:917-24.","DOI":"10.3233\/JPD-230104"},{"key":"key-10.14336\/AD.2025.0619-21","doi-asserted-by":"crossref","unstructured":"Cullinane PW, De Pablo Fernandez E, K\u00f6nig A, Outeiro TF, Jaunmuktane Z, Warner TT (2023). Type 2 Diabetes and Parkinson\u2019s Disease: A Focused Review of Current Concepts. Mov Disord, 38:162-77.","DOI":"10.1002\/mds.29298"},{"key":"key-10.14336\/AD.2025.0619-22","doi-asserted-by":"crossref","unstructured":"Somjen GG (1988). Nervenkitt: Notes on the history of the concept of neuroglia. Glia, 1:2-9.","DOI":"10.1002\/glia.440010103"},{"key":"key-10.14336\/AD.2025.0619-23","doi-asserted-by":"crossref","unstructured":"Almeida A, Almeida J, Bola\u00f1os JP, Moncada S (2001). Different responses of astrocytes and neurons to nitric oxide: The role of glycolytically generated ATP in astrocyte protection. Proc Natl Acad Sci U S A, 98:15294-9.","DOI":"10.1073\/pnas.261560998"},{"key":"key-10.14336\/AD.2025.0619-24","doi-asserted-by":"crossref","unstructured":"Almeida A, Moncada S, Bola\u00f1os JP (2004). Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat Cell Biol, 6:45-51.","DOI":"10.1038\/ncb1080"},{"key":"key-10.14336\/AD.2025.0619-25","doi-asserted-by":"crossref","unstructured":"Herrero-Mendez A, Almeida A, Fern\u00e1ndez E, Maestre C, Moncada S, Bola\u00f1os JP (2009). The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC\/C-Cdh1. Nat Cell Biol, 11:747-52.","DOI":"10.1038\/ncb1881"},{"key":"key-10.14336\/AD.2025.0619-26","doi-asserted-by":"crossref","unstructured":"D\u00edaz\u2010Garc\u00eda CM, Yellen G (2019). Neurons rely on glucose rather than astrocytic lactate during stimulation. J Neurosci Res, 97:883-9.","DOI":"10.1002\/jnr.24374"},{"key":"key-10.14336\/AD.2025.0619-27","doi-asserted-by":"crossref","unstructured":"Fujino Y, Kasai T, Kitani-Morii F, Ohmichi T, Shinomoto M, Menjo K, et al (2021). Impaired age-dependent increases in phosphoglycerate kinase activity in red blood cells of Parkinson\u2019s disease patients. Parkinsonism Relat Disord, 91:128-34.","DOI":"10.1016\/j.parkreldis.2021.09.016"},{"key":"key-10.14336\/AD.2025.0619-28","doi-asserted-by":"crossref","unstructured":"Fernandes HJR, Patikas N, Foskolou S, Field SF, Park J-E, Byrne ML, et al (2020). Single-Cell Transcriptomics of Parkinson\u2019s Disease Human In Vitro Models Reveals Dopamine Neuron-Specific Stress Responses. Cell Rep, 33:108263.","DOI":"10.1016\/j.celrep.2020.108263"},{"key":"key-10.14336\/AD.2025.0619-29","doi-asserted-by":"crossref","unstructured":"Solana-Manrique C, Sanz FJ, Ripoll\u00e9s E, Ba\u00f1\u00f3 MC, Torres J, Mu\u00f1oz-Soriano V, et al (2020). Enhanced activity of glycolytic enzymes in Drosophila and human cell models of Parkinson\u2019s disease based on DJ-1 deficiency. Free Radic Biol Med, 158:137-148.","DOI":"10.1016\/j.freeradbiomed.2020.06.036"},{"key":"key-10.14336\/AD.2025.0619-30","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves DF, Duarte T, Foletto JVP, Senger LR, Barbosa NBV, Soares FAA, et al (2022). Mitochondrial function and cellular energy maintenance during aging in a Drosophila melanogaster model of Parkinson disease. Mitochondrion, 65:166-75.","DOI":"10.1016\/j.mito.2022.06.007"},{"key":"key-10.14336\/AD.2025.0619-31","doi-asserted-by":"crossref","unstructured":"Pathania A, Garg P, Sandhir R (2021). Impaired mitochondrial functions and energy metabolism in MPTP-induced Parkinson\u2019s disease: comparison of mice strains and dose regimens. Metab Brain Dis, 36:2343-57.","DOI":"10.1007\/s11011-021-00840-2"},{"key":"key-10.14336\/AD.2025.0619-32","doi-asserted-by":"crossref","unstructured":"Danileviciute E, Zeng N, Capelle CM, Paczia N, Gillespie MA, Kurniawan H, et al (2022). PARK7\/DJ-1 promotes pyruvate dehydrogenase activity and maintains Treg homeostasis during ageing. Nat Metab, 4:589-607.","DOI":"10.1038\/s42255-022-00576-y"},{"key":"key-10.14336\/AD.2025.0619-33","doi-asserted-by":"crossref","unstructured":"Miki Y, Tanji K, Mori F, Kakita A, Takahashi H, Wakabayashi K (2017). Alteration of mitochondrial protein PDHA1 in Lewy body disease and PARK14. Biochem Biophys Res Commun, 489:439-44.","DOI":"10.1016\/j.bbrc.2017.05.162"},{"key":"key-10.14336\/AD.2025.0619-34","doi-asserted-by":"crossref","unstructured":"Ahmed SS, Santosh W, Kumar S, Christlet HTT (2009). Metabolic profiling of Parkinson\u2019s disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci, 16:63.","DOI":"10.1186\/1423-0127-16-63"},{"key":"key-10.14336\/AD.2025.0619-35","doi-asserted-by":"crossref","unstructured":"Zhu J, Xu F, Lai H, Yuan H, Li X-Y, Hu J, et al (2023). ACO2 deficiency increases vulnerability to Parkinson\u2019s disease via dysregulating mitochondrial function and histone acetylation-mediated transcription of autophagy genes. Commun Biol, 6:1201.","DOI":"10.1038\/s42003-023-05570-y"},{"key":"key-10.14336\/AD.2025.0619-36","doi-asserted-by":"crossref","unstructured":"Gibson GE, Kingsbury AE, Xu H, Lindsay JG, Daniel S, Foster OJF, et al (2003). Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson\u2019s disease. Neurochem Int, 43:129-35.","DOI":"10.1016\/S0197-0186(02)00225-5"},{"key":"key-10.14336\/AD.2025.0619-37","doi-asserted-by":"crossref","unstructured":"Toomey CE, Heywood WE, Evans JR, Lachica J, Pressey SN, Foti SC, et al (2022). Mitochondrial dysfunction is a key pathological driver of early stage Parkinson\u2019s. Acta Neuropathol Commun, 10:134.","DOI":"10.1186\/s40478-022-01424-6"},{"key":"key-10.14336\/AD.2025.0619-38","doi-asserted-by":"crossref","unstructured":"Ikuno M, Yamakado H, Amano I, Hatanaka Y, Uemura N, Matsuzawa S, et al (2021). Mitochondrial dysfunction in a mouse model of prodromal Parkinson\u2019s disease: A metabolomic analysis. Neurosci Lett, 765:136267.","DOI":"10.1016\/j.neulet.2021.136267"},{"key":"key-10.14336\/AD.2025.0619-39","doi-asserted-by":"crossref","unstructured":"Vos M, Dulovic-Mahlow M, Mandik F, Frese L, Kanana Y, Haissatou Diaw S, et al (2021). Ceramide accumulation induces mitophagy and impairs \u03b2-oxidation in PINK1 deficiency. Proc Natl Acad Sci U S A, 118:e2025347118.","DOI":"10.1073\/pnas.2025347118"},{"key":"key-10.14336\/AD.2025.0619-40","doi-asserted-by":"crossref","unstructured":"Di Lazzaro G, Magrinelli F, Estevez\u2010Fraga C, Valente EM, Pisani A, Bhatia KP (2021). X\u2010Linked Parkinsonism: Phenotypic and Genetic Heterogeneity. Mov Disord, 36:1511-25.","DOI":"10.1002\/mds.28565"},{"key":"key-10.14336\/AD.2025.0619-41","doi-asserted-by":"crossref","unstructured":"Sakaue S, Kasai T, Mizuta I, Suematsu M, Osone S, Azuma Y, et al (2017). Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: do PGK-1 mutations contribute to vulnerability to parkinsonism? NPJ Parkinsons Dis, 3:13.","DOI":"10.1038\/s41531-017-0014-4"},{"key":"key-10.14336\/AD.2025.0619-42","doi-asserted-by":"crossref","unstructured":"Morales-Brice\u00f1o H, Ha AD, London K, Farlow D, Chang FCF, Fung VSC (2019). Parkinsonism in PGK1 deficiency implicates the glycolytic pathway in nigrostriatal dysfunction. Parkinsonism Relat Disord, 64:319-23.","DOI":"10.1016\/j.parkreldis.2019.04.004"},{"key":"key-10.14336\/AD.2025.0619-43","doi-asserted-by":"crossref","unstructured":"Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, et al (2019). Enhancing glycolysis attenuates Parkinson\u2019s disease progression in models and clinical databases. J Clin Invest, 129:4539-49.","DOI":"10.1172\/JCI129987"},{"key":"key-10.14336\/AD.2025.0619-44","doi-asserted-by":"crossref","unstructured":"Shimizu J, Kasai T, Yoshida H, Huynh AM, Nakao-Azuma Y, Shinomoto M, et al (2020). Novel Drosophila model for parkinsonism by targeting phosphoglycerate kinase. Neurochem Int, 139:104816.","DOI":"10.1016\/j.neuint.2020.104816"},{"key":"key-10.14336\/AD.2025.0619-45","doi-asserted-by":"crossref","unstructured":"Fang J, Wang X, Cao G, Wang F, Ru Y, Wang B, et al (2024). 6PPD-quinone exposure induces neuronal mitochondrial dysfunction to exacerbate Lewy neurites formation induced by \u03b1-synuclein preformed fibrils seeding. J Hazard Mater, 465:133312.","DOI":"10.1016\/j.jhazmat.2023.133312"},{"key":"key-10.14336\/AD.2025.0619-46","doi-asserted-by":"crossref","unstructured":"Mallet D, Dufourd T, Decourt M, Carcenac C, Boss\u00f9 P, Verlin L, et al (2022). A metabolic biomarker predicts Parkinson\u2019s disease at the early stages in patients and animal models. J Clin Invest, 132:e146400.","DOI":"10.1172\/JCI146400"},{"key":"key-10.14336\/AD.2025.0619-47","doi-asserted-by":"crossref","unstructured":"Kim HN, Shin JY, Kim DY, Lee JE, Lee PH (2021). Priming mesenchymal stem cells with uric acid enhances neuroprotective properties in parkinsonian models. J Tissue Eng, 12:20417314211004816.","DOI":"10.1177\/20417314211004816"},{"key":"key-10.14336\/AD.2025.0619-48","doi-asserted-by":"crossref","unstructured":"Sanz FJ, Solana-Manrique C, Torres J, Masi\u00e1 E, Vicent MJ, Paricio N (2021). A High-Throughput Chemical Screen in DJ-1\u03b2 Mutant Flies Identifies Zaprinast as a Potential Parkinson\u2019s Disease Treatment. Neurotherapeutics, 18:2565-78.","DOI":"10.1007\/s13311-021-01134-2"},{"key":"key-10.14336\/AD.2025.0619-49","doi-asserted-by":"crossref","unstructured":"Ren M, Yang Y, Heng KHY, Ng LY, Chong CY-Y, Ng YT, et al (2022). MED13 and glycolysis are conserved modifiers of \u03b1-synuclein-associated neurodegeneration. Cell Rep, 41:111852.","DOI":"10.1016\/j.celrep.2022.111852"},{"key":"key-10.14336\/AD.2025.0619-50","doi-asserted-by":"crossref","unstructured":"Rey F, Ottolenghi S, Giallongo T, Balsari A, Martinelli C, Rey R, et al (2021). Mitochondrial Metabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson\u2019s Disease. Antioxidants (Basel), 10:121.","DOI":"10.3390\/antiox10010121"},{"key":"key-10.14336\/AD.2025.0619-51","doi-asserted-by":"crossref","unstructured":"Zhang S, Wang S, Shi X, Feng X (2020). Polydatin alleviates parkinsonism in MPTP-model mice by enhancing glycolysis in dopaminergic neurons. Neurochem Int, 139:104815.","DOI":"10.1016\/j.neuint.2020.104815"},{"key":"key-10.14336\/AD.2025.0619-52","doi-asserted-by":"crossref","unstructured":"Yang S-Q, Tian Q, Li D, He S-Q, Hu M, Liu S-Y, et al (2020). Leptin mediates protection of hydrogen sulfide against 6-hydroxydopamine-induced Parkinson\u2019s disease: Involving enhancement in Warburg effect. Neurochem Int, 135:104692.","DOI":"10.1016\/j.neuint.2020.104692"},{"key":"key-10.14336\/AD.2025.0619-53","doi-asserted-by":"crossref","unstructured":"Ribeiro GBES, Rodrigues FR, Pasqualotto E, Dantas JM, Di Luca DG (2024). Exposure to Glycolysis-Enhancing Drugs and Risk of Parkinson\u2019s Disease: A Meta-Analysis. J Parkinsons Dis, 14:1237-42.","DOI":"10.3233\/JPD-240104"},{"key":"key-10.14336\/AD.2025.0619-54","unstructured":"Yang CH, Raja A.Terazosin. StatPearls, Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"key-10.14336\/AD.2025.0619-55","doi-asserted-by":"crossref","unstructured":"Weber MA, Sivakumar K, Tabakovic EE, Oya M, Aldridge GM, Zhang Q, et al (2023). Glycolysis-enhancing \u03b11-adrenergic antagonists modify cognitive symptoms related to Parkinson\u2019s disease. NPJ Parkinsons Dis, 9:32.","DOI":"10.1038\/s41531-023-00477-1"},{"key":"key-10.14336\/AD.2025.0619-56","doi-asserted-by":"crossref","unstructured":"Simmering JE, Welsh MJ, Schultz J, Narayanan NS (2022). Use of Glycolysis\u2010Enhancing Drugs and Risk of Parkinson\u2019s Disease. Mov Disord, 37:2210-6.","DOI":"10.1002\/mds.29184"},{"key":"key-10.14336\/AD.2025.0619-57","doi-asserted-by":"crossref","unstructured":"Schultz JL, Brinker AN, Xu J, Ernst SE, Tayyari F, Rauchkorst, et al (2022). A pilot to assess target engagement of terazosin in Parkinson's disease. Parkinsonism Relat Disord, 94:79-83.","DOI":"10.1016\/j.parkreldis.2021.11.022"},{"key":"key-10.14336\/AD.2025.0619-58","doi-asserted-by":"crossref","unstructured":"McCune SK, Voigt MM, Hill\u2021 JM (1993). Expression of multiple alpha adrenergic receptor subtype messenger RNAs in the adult rat brain. Neuroscience, 57:143-51.","DOI":"10.1016\/0306-4522(93)90116-W"},{"key":"key-10.14336\/AD.2025.0619-59","doi-asserted-by":"crossref","unstructured":"Chen Z, Li G, Liu J (2020). Autonomic dysfunction in Parkinson\u2019s disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis, 134:104700.","DOI":"10.1016\/j.nbd.2019.104700"},{"key":"key-10.14336\/AD.2025.0619-60","doi-asserted-by":"crossref","unstructured":"Heremans IP, Caligiore F, Gerin I, Bury M, Lutz M, Graff J, et al (2022). Parkinson\u2019s disease protein PARK7 prevents metabolite and protein damage caused by a glycolytic metabolite. Proc Natl Acad Sci U S A, 119:e2111338119.","DOI":"10.1073\/pnas.2111338119"},{"key":"key-10.14336\/AD.2025.0619-61","doi-asserted-by":"crossref","unstructured":"Akhmadi A, Yeskendir A, Dey N, Mussakhmetov A, Shatkenova Z, Kulyyassov A, et al (2024). DJ-1 protects proteins from acylation by catalyzing the hydrolysis of highly reactive cyclic 3-phosphoglyceric anhydride. Nat Commun, 15:2004.","DOI":"10.1038\/s41467-024-46391-9"},{"key":"key-10.14336\/AD.2025.0619-62","doi-asserted-by":"crossref","unstructured":"Thornalley PJ, Langborg A, Minhas HS (1999). Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J, 344 Pt 1:109-16.","DOI":"10.1042\/bj3440109"},{"key":"key-10.14336\/AD.2025.0619-63","doi-asserted-by":"crossref","unstructured":"Cheg\u00e3o A, Guarda M, Alexandre BM, Shvachiy L, Temido-Ferreira M, Marques-Morgado I, et al (2022). Glycation modulates glutamatergic signaling and exacerbates Parkinson\u2019s disease-like phenotypes. NPJ Parkinsons Dis, 8:51.","DOI":"10.1038\/s41531-022-00314-x"},{"key":"key-10.14336\/AD.2025.0619-64","doi-asserted-by":"crossref","unstructured":"Xie B, Lin F, Ullah K, Peng L, Ding W, Dai R, et al (2015). A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson\u2019s disease. Biochem Biophys Res Commun, 459:361-6.","DOI":"10.1016\/j.bbrc.2015.02.069"},{"key":"key-10.14336\/AD.2025.0619-65","doi-asserted-by":"crossref","unstructured":"Omoto S, Saito M, Murakami H, Shiraishi T, Kitagawa T, Sato T, et al (2022). The association between urinary pentosidine levels and cognition in drug-na\u00efve patients with Parkinson\u2019s disease. Neurol Sci, 43:6323-8.","DOI":"10.1007\/s10072-022-06332-0"},{"key":"key-10.14336\/AD.2025.0619-66","doi-asserted-by":"crossref","unstructured":"Morrone Parfitt G, Coccia E, Goldman C, Whitney K, Reyes R, Sarrafha L, et al (2024). Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson\u2019s disease model. Nat Commun, 15:447.","DOI":"10.1038\/s41467-024-44732-2"},{"key":"key-10.14336\/AD.2025.0619-67","doi-asserted-by":"crossref","unstructured":"Tatton NA (2000). Increased Caspase 3 and Bax Immunoreactivity Accompany Nuclear GAPDH Translocation and Neuronal Apoptosis in Parkinson\u2019s Disease. Exp Neurol, 166:29-43.","DOI":"10.1006\/exnr.2000.7489"},{"key":"key-10.14336\/AD.2025.0619-68","doi-asserted-by":"crossref","unstructured":"Melnikova A, Pozdyshev D, Barinova K, Kudryavtseva S, Muronetz VI (2020). \u03b1-Synuclein Overexpression in SH-SY5Y Human Neuroblastoma Cells Leads to the Accumulation of Thioflavin S-positive Aggregates and Impairment of Glycolysis. Biochemistry (Mosc), 85:604-13.","DOI":"10.1134\/S0006297920050090"},{"key":"key-10.14336\/AD.2025.0619-69","doi-asserted-by":"crossref","unstructured":"Ping Z, Fan H, Wen C, Ji Z, Liang S (2021). GAPDH siRNA Regulates SH-SY5Y Cell Apoptosis Induced by Exogenous \u03b1-Synuclein Protein. Neuroscience, 469:91-102.","DOI":"10.1016\/j.neuroscience.2021.06.035"},{"key":"key-10.14336\/AD.2025.0619-70","unstructured":"Borghammer P (2012). Perfusion and metabolism imaging studies in Parkinson\u2019s disease. Dan Med J, 59:B4466."},{"key":"key-10.14336\/AD.2025.0619-71","doi-asserted-by":"crossref","unstructured":"Dunn L, Allen GFg, Mamais A, Ling H, Li A, Duberley KE, et al (2014). Dysregulation of glucose metabolism is an early event in sporadic Parkinson\u2019s disease. Neurobiol Aging, 35:1111-5.","DOI":"10.1016\/j.neurobiolaging.2013.11.001"},{"key":"key-10.14336\/AD.2025.0619-72","doi-asserted-by":"crossref","unstructured":"Eggers C, Schwartz F, Pedrosa DJ, Kracht L, Timmermann L (2014). Parkinson\u2019s Disease Subtypes Show a Specific Link between Dopaminergic and Glucose Metabolism in the Striatum. PLoS One, 9:e96629.","DOI":"10.1371\/journal.pone.0096629"},{"key":"key-10.14336\/AD.2025.0619-73","doi-asserted-by":"crossref","unstructured":"Mischley LK, Shankland E, Liu SZ, Bhayana S, Fox DJ, Marcinek DJ (2023). ATP and NAD+ Deficiency in Parkinson\u2019s Disease. Nutrients, 15:943.","DOI":"10.3390\/nu15040943"},{"key":"key-10.14336\/AD.2025.0619-74","doi-asserted-by":"crossref","unstructured":"Luo Q, Yang Y, Xian C, Zhou P, Zhang H, Lv Z, et al (2024). Nicotinamide riboside ameliorates survival time and motor dysfunction in an MPTP-Induced Parkinson\u2019s disease zebrafish model through effects on glucose metabolism and endoplasmic reticulum stress. Chem Biol Interact, 399:111118.","DOI":"10.1016\/j.cbi.2024.111118"},{"key":"key-10.14336\/AD.2025.0619-75","doi-asserted-by":"crossref","unstructured":"Brakedal B, D\u00f6lle C, Riemer F, Ma Y, Nido GS, Skeie GO, et al (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson\u2019s disease. Cell Metab, 34:396-407.e6.","DOI":"10.1016\/j.cmet.2022.02.001"},{"key":"key-10.14336\/AD.2025.0619-76","doi-asserted-by":"crossref","unstructured":"Chen B, Zhang Q, Zhong X, Zhang X, Liu X, Wang H, et al (2024). Dopamine modification of glycolytic enzymes impairs glycolysis: possible implications for Parkinson\u2019s disease. Cell Commun Signal, 22:75.","DOI":"10.1186\/s12964-024-01478-0"},{"key":"key-10.14336\/AD.2025.0619-77","doi-asserted-by":"crossref","unstructured":"Sofroniew MV, Vinters HV (2010). Astrocytes: biology and pathology. Acta Neuropathol, 119:7-35.","DOI":"10.1007\/s00401-009-0619-8"},{"key":"key-10.14336\/AD.2025.0619-78","doi-asserted-by":"crossref","unstructured":"Ferguson BS, Rogatzki MJ, Goodwin ML, Kane DA, Rightmire Z, Gladden LB (2018). Lactate metabolism: historical context, prior misinterpretations, and current understanding. Eur J Appl Physio, 118:691-728.","DOI":"10.1007\/s00421-017-3795-6"},{"key":"key-10.14336\/AD.2025.0619-79","doi-asserted-by":"crossref","unstructured":"B\u00e9langer M, Allaman I, Magistretti PJ (2011). Brain Energy Metabolism: Focus on Astrocyte-Neuron Metabolic Cooperation. Cell Metab, 14:724-38.","DOI":"10.1016\/j.cmet.2011.08.016"},{"key":"key-10.14336\/AD.2025.0619-80","doi-asserted-by":"crossref","unstructured":"Pellerin L, Pellegri G, Bittar PG, Charnay Y, Bouras C, Martin J-L, et al (1998). Evidence Supporting the Existence of an Activity-Dependent Astrocyte-Neuron Lactate Shuttle. Dev Neurosci, 20:291-9.","DOI":"10.1159\/000017324"},{"key":"key-10.14336\/AD.2025.0619-81","doi-asserted-by":"crossref","unstructured":"Yang C, Pan R-Y, Guan F, Yuan Z (2024). Lactate metabolism in neurodegenerative diseases. Neural Regen Res, 19:69-74.","DOI":"10.4103\/1673-5374.374142"},{"key":"key-10.14336\/AD.2025.0619-82","doi-asserted-by":"crossref","unstructured":"Liberti MV, Locasale JW (2016). The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci, 41:211-8.","DOI":"10.1016\/j.tibs.2015.12.001"},{"key":"key-10.14336\/AD.2025.0619-83","doi-asserted-by":"crossref","unstructured":"Potter M, Newport E, Morten KJ (2016). The Warburg effect: 80 years on. Biochem Soc Trans, 44:1499-505.","DOI":"10.1042\/BST20160094"},{"key":"key-10.14336\/AD.2025.0619-84","doi-asserted-by":"crossref","unstructured":"Li J, Chen L, Qin Q, Wang D, Zhao J, Gao H, et al (2022). Upregulated hexokinase 2 expression induces the apoptosis of dopaminergic neurons by promoting lactate production in Parkinson\u2019s disease. Neurobiol Dis, 163:105605.","DOI":"10.1016\/j.nbd.2021.105605"},{"key":"key-10.14336\/AD.2025.0619-85","doi-asserted-by":"crossref","unstructured":"Schirinzi T, Di Lazzaro G, Sancesario GM, Summa S, Petrucci S, Colona VL, et al (2020). Young-onset and late-onset Parkinson\u2019s disease exhibit a different profile of fluid biomarkers and clinical features. Neurobiol Aging, 90:119-24.","DOI":"10.1016\/j.neurobiolaging.2020.02.012"},{"key":"key-10.14336\/AD.2025.0619-86","doi-asserted-by":"crossref","unstructured":"Liguori C, Stefani A, Fernandes M, Cerroni R, Mercuri NB, Pierantozzi M (2022). Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson\u2019s Disease: A Cerebrospinal Fluid-Based Study. J Parkinsons Dis,12:537-44.","DOI":"10.3233\/JPD-212936"},{"key":"key-10.14336\/AD.2025.0619-87","doi-asserted-by":"crossref","unstructured":"Lian B, Zhang J, Yin X, Wang J, Li L, Ju Q, et al (2024). SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of PKM2. Cell Rep Med, 5:101684.","DOI":"10.1016\/j.xcrm.2024.101684"},{"key":"key-10.14336\/AD.2025.0619-88","doi-asserted-by":"crossref","unstructured":"Komilova NR, Angelova PR, Berezhnov AV, Stelmashchuk OA, Mirkhodjaev UZ, Houlden H, et al (2022). Metabolically induced intracellular pH changes activate mitophagy, autophagy, and cell protection in familial forms of Parkinson\u2019s disease. FEBS J, 289:699-711.","DOI":"10.1111\/febs.16198"},{"key":"key-10.14336\/AD.2025.0619-89","doi-asserted-by":"crossref","unstructured":"Fedotova EI, Dolgacheva LP, Abramov AY, Berezhnov AV (2022). Lactate and Pyruvate Activate Autophagy and Mitophagy that Protect Cells in Toxic Model of Parkinson\u2019s Disease. Mol Neurobiol, 59:177-90.","DOI":"10.1007\/s12035-021-02583-8"},{"key":"key-10.14336\/AD.2025.0619-90","doi-asserted-by":"crossref","unstructured":"Cheng J, Zhang R, Xu Z, Ke Y, Sun R, Yang H, et al (2021). Early glycolytic reprogramming controls microglial inflammatory activation. J Neuroinflammation, 18:129.","DOI":"10.1186\/s12974-021-02187-y"},{"key":"key-10.14336\/AD.2025.0619-91","doi-asserted-by":"crossref","unstructured":"Lu J, Wang C, Cheng X, Wang R, Yan X, He P, et al (2022). A breakdown in microglial metabolic reprogramming causes internalization dysfunction of \u03b1-synuclein in a mouse model of Parkinson\u2019s disease. J Neuroinflammation, 19:113.","DOI":"10.1186\/s12974-022-02484-0"},{"key":"key-10.14336\/AD.2025.0619-92","doi-asserted-by":"crossref","unstructured":"Andersson AK, R\u00f6nnb\u00e4ck L, Hansson E (2005). Lactate induces tumour necrosis factor\u2010\u03b1 interleukin\u20106 and interleukin\u20101\u03b2 release in microglial\u2010 and astroglial\u2010enriched primary cultures. J Neurochem, 93:1327-33.","DOI":"10.1111\/j.1471-4159.2005.03132.x"},{"key":"key-10.14336\/AD.2025.0619-93","doi-asserted-by":"crossref","unstructured":"Xu Y, Liu C, Chen S, Ye Y, Guo M, Ren Q, et al (2014). Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson\u2019s disease. Cell Signal, 26:1680-9.","DOI":"10.1016\/j.cellsig.2014.04.009"},{"key":"key-10.14336\/AD.2025.0619-94","doi-asserted-by":"crossref","unstructured":"Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, et al (2011). Resveratrol-Activated AMPK\/SIRT1\/Autophagy in Cellular Models of Parkinson\u2019s Disease. Neurosignals, 19:163-74.","DOI":"10.1159\/000328516"},{"key":"key-10.14336\/AD.2025.0619-95","doi-asserted-by":"crossref","unstructured":"Muraleedharan R, Gawali MV, Tiwari D, Sukumaran A, Oatman N, Anderson J, et al (2020). AMPK-Regulated Astrocytic Lactate Shuttle Plays a Non-Cell-Autonomous Role in Neuronal Survival. Cell Rep, 32:108092.","DOI":"10.1016\/j.celrep.2020.108092"},{"key":"key-10.14336\/AD.2025.0619-96","doi-asserted-by":"crossref","unstructured":"Shen Z, Jiang L, Yuan Y, Deng T, Zheng Y, Zhao Y, et al (2015). Inhibition of G Protein\u2010Coupled Receptor 81 (GPR 81) Protects Against Ischemic Brain Injury. CNS Neurosci Ther, 21:271-9.","DOI":"10.1111\/cns.12362"},{"key":"key-10.14336\/AD.2025.0619-97","doi-asserted-by":"crossref","unstructured":"Hung YP, Albeck JG, Tantama M, Yellen G (2011). Imaging Cytosolic NADH-NAD+ Redox State with a Genetically Encoded Fluorescent Biosensor. Cell Metab, 14:545-54.","DOI":"10.1016\/j.cmet.2011.08.012"},{"key":"key-10.14336\/AD.2025.0619-98","doi-asserted-by":"crossref","unstructured":"Zagare A, Preciat G, Nickels SarahL, Luo X, Monzel AS, Gomez-Giro G, et al (2023). Omics data integration suggests a potential idiopathic Parkinson\u2019s disease signature. Commun Biol, 6:1179.","DOI":"10.1038\/s42003-023-05548-w"},{"key":"key-10.14336\/AD.2025.0619-99","doi-asserted-by":"crossref","unstructured":"Jiao J, Gao G, Zhu J, Wang C, Liu L, Yang H (2024). Binding of \u03b1-synuclein to ACO2 promotes progressive mitochondrial dysfunction in Parkinson\u2019s disease models. Redox Biol, 77:103399.","DOI":"10.1016\/j.redox.2024.103399"},{"key":"key-10.14336\/AD.2025.0619-100","doi-asserted-by":"crossref","unstructured":"Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe S (1994). An immunohistochemical study on \u03b1\u2010ketoglutarate dehydrogenase complex in Parkinson\u2019s disease. Ann Neurol, 35:204-10.","DOI":"10.1002\/ana.410350212"},{"key":"key-10.14336\/AD.2025.0619-101","doi-asserted-by":"crossref","unstructured":"Chen H, Denton TT, Xu H, Calingasan N, Beal MF, Gibson GE (2016). Reductions in the mitochondrial enzyme \u03b1\u2010ketoglutarate dehydrogenase complex in neurodegenerative disease - beneficial or detrimental? J Neurochem, 139:823-38.","DOI":"10.1111\/jnc.13836"},{"key":"key-10.14336\/AD.2025.0619-102","doi-asserted-by":"crossref","unstructured":"Doulias P-T, Yang H, Andreyev AY, Dolatabadi N, Scott H, K Raspur C, et al (2023). S-Nitrosylation-mediated dysfunction of TCA cycle enzymes in synucleinopathy studied in postmortem human brains and hiPSC-derived neurons. Cell Chem Biol, 30:965-975.e6.","DOI":"10.1016\/j.chembiol.2023.06.018"},{"key":"key-10.14336\/AD.2025.0619-103","doi-asserted-by":"crossref","unstructured":"Cui X-X, Li X, Dong S-Y, Guo Y-J, Liu T, Wu Y-C (2017). SIRT3 deacetylated and increased citrate synthase activity in PD model. Biochem Biophys Res Commun, 484:767-73.","DOI":"10.1016\/j.bbrc.2017.01.163"},{"key":"key-10.14336\/AD.2025.0619-104","doi-asserted-by":"crossref","unstructured":"Buoso C, Seifert M, Lang M, Griffith CM, Talavera And\u00fajar B, Castelo Rueda MP, et al (2024). Dopamine\u2011iron homeostasis interaction rescues mitochondrial fitness in Parkinson\u2019s disease. Neurobiol Dis, 196:106506.","DOI":"10.1016\/j.nbd.2024.106506"},{"key":"key-10.14336\/AD.2025.0619-105","doi-asserted-by":"crossref","unstructured":"Yang J, Kim MJ, Yoon W, Kim EY, Kim H, Lee Y, et al (2017). Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP+-dependent isocitrate dehydrogenase (IDH). PLoS Genet, 13:e1006975","DOI":"10.1371\/journal.pgen.1006975"},{"key":"key-10.14336\/AD.2025.0619-106","doi-asserted-by":"crossref","unstructured":"Luo Y, Sakamoto K (2023). Ethyl pyruvate protects SHSY5Y cells against 6-hydroxydopamine-induced neurotoxicity by upregulating autophagy. PLoS ONE, 18:e0281957.","DOI":"10.1371\/journal.pone.0281957"},{"key":"key-10.14336\/AD.2025.0619-107","doi-asserted-by":"crossref","unstructured":"Kim Y-M, Choi SY, Hwang O, Lee J-Y (2022). Pyruvate Prevents Dopaminergic Neurodegeneration and Motor Deficits in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson\u2019s Disease. Mol Neurobiol, 59:6956-70.","DOI":"10.1007\/s12035-022-03017-9"},{"key":"key-10.14336\/AD.2025.0619-108","doi-asserted-by":"crossref","unstructured":"Ebert D, Haller RG, Walton ME (2003). Energy Contribution of Octanoate to Intact Rat Brain Metabolism Measured by13 C Nuclear Magnetic Resonance Spectroscopy. J Neurosci, 23:5928-35.","DOI":"10.1523\/JNEUROSCI.23-13-05928.2003"},{"key":"key-10.14336\/AD.2025.0619-109","doi-asserted-by":"crossref","unstructured":"Tracey TJ, Steyn FJ, Wolvetang EJ, Ngo ST (2018). Neuronal Lipid Metabolism: Multiple Pathways Driving Functional Outcomes in Health and Disease. Front Mol Neurosci, 11:10.","DOI":"10.3389\/fnmol.2018.00010"},{"key":"key-10.14336\/AD.2025.0619-110","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nfeld P, Reiser G (2013). Why does Brain Metabolism not Favor Burning of Fatty Acids to Provide Energy? - Reflections on Disadvantages of the Use of Free Fatty Acids as Fuel for Brain. J Cereb Blood Flow Metab, 33:1493-9.","DOI":"10.1038\/jcbfm.2013.128"},{"key":"key-10.14336\/AD.2025.0619-111","doi-asserted-by":"crossref","unstructured":"Fecher C, Trov\u00f2 L, M\u00fcller SA, Snaidero N, Wettmarshausen J, Heink S, et al (2019). Cell-type-specific profiling of brain mitochondria reveals functional and molecular diversity. Nat Neurosci, 22:1731-42.","DOI":"10.1038\/s41593-019-0479-z"},{"key":"key-10.14336\/AD.2025.0619-112","doi-asserted-by":"crossref","unstructured":"Fitzner D, Bader JM, Penkert H, Bergner CG, Su M, Weil M-T, et al (2020). Cell-Type- and Brain-Region-Resolved Mouse Brain Lipidome. Cell Rep, 32:108132.","DOI":"10.1016\/j.celrep.2020.108132"},{"key":"key-10.14336\/AD.2025.0619-113","doi-asserted-by":"crossref","unstructured":"Satoh T.Supply of Energy Substrate to the Brain. Hybrid-Powered Brain, Cham: Springer Nature Switzerland; 2024, p. 65-75.","DOI":"10.1007\/978-3-031-54150-6_5"},{"key":"key-10.14336\/AD.2025.0619-114","doi-asserted-by":"crossref","unstructured":"Prins ML (2008). Cerebral Metabolic Adaptation and Ketone Metabolism after Brain Injury. J Cereb Blood Flow Metab, 28:1-16.","DOI":"10.1038\/sj.jcbfm.9600543"},{"key":"key-10.14336\/AD.2025.0619-115","doi-asserted-by":"crossref","unstructured":"Fanning S, Haque A, Imberdis T, Baru V, Barrasa MI, Nuber S, et al (2019). Lipidomic Analysis of \u03b1-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. Mol Cell, 73:1001-1014.e8.","DOI":"10.1016\/j.molcel.2018.11.028"},{"key":"key-10.14336\/AD.2025.0619-116","doi-asserted-by":"crossref","unstructured":"Luan H, Liu L-F, Meng N, Tang Z, Chua K-K, Chen L-L, et al (2015). LC-MS-Based Urinary Metabolite Signatures in Idiopathic Parkinson\u2019s Disease. J Proteome Res, 14:467-78.","DOI":"10.1021\/pr500807t"},{"key":"key-10.14336\/AD.2025.0619-117","doi-asserted-by":"crossref","unstructured":"Longo N, Frigeni M, Pasquali M (2016). Carnitine transport and fatty acid oxidation. Biochim Biophys Acta, 1863:2422-35.","DOI":"10.1016\/j.bbamcr.2016.01.023"},{"key":"key-10.14336\/AD.2025.0619-118","doi-asserted-by":"crossref","unstructured":"Kler RS, Jackson S, Bartlett K, Bindoff LA, Eaton S, Pourfarzam M, et al (1991). Quantitation of acyl-CoA and acylcarnitine esters accumulated during abnormal mitochondrial fatty acid oxidation. J Biol Chem, 266:22932-8","DOI":"10.1016\/S0021-9258(18)54444-6"},{"key":"key-10.14336\/AD.2025.0619-119","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez Campos S, Alza NP, Salvador GA (2018). Lipid metabolism alterations in the neuronal response to A53T \u03b1-synuclein and Fe-induced injury. Arch Biochem Biophys, 655:43-54.","DOI":"10.1016\/j.abb.2018.08.007"},{"key":"key-10.14336\/AD.2025.0619-120","doi-asserted-by":"crossref","unstructured":"Miyamoto K, Saiki S, Matsumoto H, Suzuki A, Yamashita Y, Iseki T, et al (2023). Systemic Metabolic Alteration Dependent on the Thyroid\u2010Liver Axis in Early PD. Ann Neurol, 93:303-16.","DOI":"10.1002\/ana.26510"},{"key":"key-10.14336\/AD.2025.0619-121","doi-asserted-by":"crossref","unstructured":"Saiki S, Hatano T, Fujimaki M, Ishikawa K-I, Mori A, Oji Y, et al (2017). Decreased long-chain acylcarnitines from insufficient \u03b2-oxidation as potential early diagnostic markers for Parkinson\u2019s disease. Sci Rep, 7:7328.","DOI":"10.1038\/s41598-017-06767-y"},{"key":"key-10.14336\/AD.2025.0619-122","doi-asserted-by":"crossref","unstructured":"Madrer N, Perera ND, Uccelli NA, Abbondanza A, Andersen JV, Carsana EV, et al (2025). Neural Metabolic Networks: Key Elements of Healthy Brain Function. J Neurochem, 169:e70084.","DOI":"10.1111\/jnc.70084"},{"key":"key-10.14336\/AD.2025.0619-123","doi-asserted-by":"crossref","unstructured":"Dong M-X, Wei Y-D, Hu L (2021). Lipid metabolic dysregulation is involved in Parkinson\u2019s disease dementia. Metab Brain Dis, 36:463-70.","DOI":"10.1007\/s11011-020-00665-5"},{"key":"key-10.14336\/AD.2025.0619-124","doi-asserted-by":"crossref","unstructured":"Hu L, Huang Y-J, Wei Y-D, Li T, Ke W, Chen G-H, et al (2024). Plasma metabolomics profiles indicate sex differences of lipid metabolism in patients with Parkinson\u2019s disease. Sci Rep, 14:31262.","DOI":"10.1038\/s41598-024-82674-3"},{"key":"key-10.14336\/AD.2025.0619-125","doi-asserted-by":"crossref","unstructured":"Qiu J, Wei L, Su Y, Tang Y, Peng G, Wu Y, et al (2013). Lipid Metabolism Disorder in Cerebrospinal Fluid Related to Parkinson\u2019s Disease. Brain Sci, 13:1166.","DOI":"10.3390\/brainsci13081166"},{"key":"key-10.14336\/AD.2025.0619-126","doi-asserted-by":"crossref","unstructured":"Li X-Y, Xue T, Lai H, Dai J, Peng F, Xu F, et al (2024). Pyruvate is modified by tea\/coffee metabolites and reversely correlated with multiple system atrophy and Parkinson\u2019s disease. Heliyon, 10:e26588.","DOI":"10.1016\/j.heliyon.2024.e26588"},{"key":"key-10.14336\/AD.2025.0619-127","doi-asserted-by":"crossref","unstructured":"Ostrakhovitch EA, Song E-S, Macedo JKA, Gentry MS, Quintero JE, Van Horne C, et al (2022). Analysis of circulating metabolites to differentiate Parkinson\u2019s disease and essential tremor. Neurosci Lett, 769:136428.","DOI":"10.1016\/j.neulet.2021.136428"},{"key":"key-10.14336\/AD.2025.0619-128","doi-asserted-by":"crossref","unstructured":"Wu G, Jiang Z, Pu Y, Chen S, Wang T, Wang Y, et al (2022). Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson\u2019s disease patients. BMC Neurol, 22:13.","DOI":"10.1186\/s12883-021-02544-7"},{"key":"key-10.14336\/AD.2025.0619-129","doi-asserted-by":"crossref","unstructured":"Toczylowska B, Zieminska E, Micha\u0142owska M, Chalimoniuk M, Fiszer U (2020). Changes in the metabolic profiles of the serum and putamen in Parkinson\u2019s disease patients - In vitro and in vivo NMR spectroscopy studies. Brain Res, 1748:147118.","DOI":"10.1016\/j.brainres.2020.147118"},{"key":"key-10.14336\/AD.2025.0619-130","doi-asserted-by":"crossref","unstructured":"Chen B, Chen X, Peng L, Liu S, Tang Y, Gao X (2024). Metabolic network connectivity disturbances in Parkinson\u2019s disease: a novel imaging biomarker. Cereb Cortex, 34:bhae355.","DOI":"10.1093\/cercor\/bhae355"},{"key":"key-10.14336\/AD.2025.0619-131","doi-asserted-by":"crossref","unstructured":"Gang M, Baba T, Hosokai Y, Nishio Y, Kikuchi A, Hirayama K, et al (2020). Clinical and Cerebral Metabolic Changes in Parkinson\u2019s Disease With Basal Forebrain Atrophy. Mov Disord, 35:825-32.","DOI":"10.1002\/mds.27988"},{"key":"key-10.14336\/AD.2025.0619-132","doi-asserted-by":"crossref","unstructured":"Isaias IU, Brumberg J, Pozzi NG, Palmisano C, Canessa A, Marotta G, et al (2020). Brain metabolic alterations herald falls in patients with Parkinson\u2019s disease. Ann Clin Transl Neurol, 7:579-83.","DOI":"10.1002\/acn3.51013"},{"key":"key-10.14336\/AD.2025.0619-133","doi-asserted-by":"crossref","unstructured":"Luo G, Shi X, Jiang L, Wu L, Yi C, Xian W, et al (2023). Effects of STN\u2010DBS surgery on cerebral glucose metabolism and distribution of DAT in Parkinson\u2019s disease. Brain Behav, 13:e3172.","DOI":"10.1002\/brb3.3172"},{"key":"key-10.14336\/AD.2025.0619-134","doi-asserted-by":"crossref","unstructured":"Oh JY, An EJ, Lee Y, Kim SM, Cheon M, Kim JY (2023). Association of dysphagia with altered brain glucose metabolism in Parkinson\u2019s disease. CNS Neurosci Ther, 29:2498-507.","DOI":"10.1111\/cns.14214"},{"key":"key-10.14336\/AD.2025.0619-135","doi-asserted-by":"crossref","unstructured":"Orso B, Arnaldi D, Peira E, Fam\u00e1 F, Giorgetti L, Girtler N, et al (2022). The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson\u2019s Disease. J Parkinsons Dis, 12:1945-55.","DOI":"10.3233\/JPD-223308"},{"key":"key-10.14336\/AD.2025.0619-136","doi-asserted-by":"crossref","unstructured":"Rao IY, Hanson LR, Johnson JC, Rosenbloom MH, Frey WH (2022). Brain Glucose Hypometabolism and Iron Accumulation in Different Brain Regions in Alzheimer\u2019s and Parkinson\u2019s Diseases. Pharmaceuticals (Basel), 15:551.","DOI":"10.3390\/ph15050551"},{"key":"key-10.14336\/AD.2025.0619-137","doi-asserted-by":"crossref","unstructured":"Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, et al (1979). The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res, 44:127-37.","DOI":"10.1161\/01.RES.44.1.127"},{"key":"key-10.14336\/AD.2025.0619-138","doi-asserted-by":"crossref","unstructured":"Prasuhn J, Schiefen T, G\u00fcber T, Henkel J, Uter J, Steinhardt J, et al (2024). Levodopa Impairs the Energy Metabolism of the Basal Ganglia In Vivo. Ann Neurol, 95:849-57.","DOI":"10.1002\/ana.26884"},{"key":"key-10.14336\/AD.2025.0619-139","doi-asserted-by":"crossref","unstructured":"Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC, Henchcliffe C (2015). Usefulness of Proton and Phosphorus MR Spectroscopic Imaging for Early Diagnosis of Parkinson\u2019s Disease. J Neuroimaging, 25:105-10.","DOI":"10.1111\/jon.12074"},{"key":"key-10.14336\/AD.2025.0619-140","doi-asserted-by":"crossref","unstructured":"Guan J, Zheng X, Lai L, Sun S, Geng Y, Zhang X, et al (2022). Proton Magnetic Resonance Spectroscopy for Diagnosis of Non-Motor Symptoms in Parkinson\u2019s Disease. Front Neurol,13:594711.","DOI":"10.3389\/fneur.2022.594711"},{"key":"key-10.14336\/AD.2025.0619-141","doi-asserted-by":"crossref","unstructured":"Gu W, He C, Chen J, Li J (2022). Proton Magnetic Resonance Spectroscopy for the Early Diagnosis of Parkinson Disease in the Substantia Nigra and Globus Pallidus: A Meta-Analysis With Trial Sequential Analysis. Front Neurol, 13:838230.","DOI":"10.3389\/fneur.2022.838230"},{"key":"key-10.14336\/AD.2025.0619-142","doi-asserted-by":"crossref","unstructured":"Firbank MJ, Harrison RM, O\u2019Brien JT (2002). A Comprehensive Review of Proton Magnetic Resonance Spectroscopy Studies in Dementia and Parkinson\u2019s Disease. Dement Geriatr Cogn Disord, 14:64-76.","DOI":"10.1159\/000064927"},{"key":"key-10.14336\/AD.2025.0619-143","doi-asserted-by":"crossref","unstructured":"DeBrosse C, Nanga RPR, Bagga P, Nath K, Haris M, Marincola F, et al (2016). Lactate Chemical Exchange Saturation Transfer (LATEST) Imaging in vivo: A Biomarker for LDH Activity. Sci Rep, 6:19517.","DOI":"10.1038\/srep21813"},{"key":"key-10.14336\/AD.2025.0619-144","doi-asserted-by":"crossref","unstructured":"Radke KL, Abrar DB, Frenken M, Wilms LM, Kamp B, Boschheidgen M, et al (2022). Chemical Exchange Saturation Transfer for Lactate-Weighted Imaging at 3 T MRI: Comprehensive In Silico, In Vitro, In Situ, and In Vivo Evaluations. Tomography, 8:1277-92.","DOI":"10.3390\/tomography8030106"},{"key":"key-10.14336\/AD.2025.0619-145","doi-asserted-by":"crossref","unstructured":"Mamoune KE, Barantin L, Adriaensen H, Tillet Y (2021). Application of Chemical Exchange Saturation Transfer (CEST) in neuroimaging. J Chem Neuroanat, 114:101944.","DOI":"10.1016\/j.jchemneu.2021.101944"},{"key":"key-10.14336\/AD.2025.0619-146","doi-asserted-by":"crossref","unstructured":"Saito S, Takahashi Y, Ohki A, Shintani Y, Higuchi T (2019). Early detection of elevated lactate levels in a mitochondrial disease model using chemical exchange saturation transfer (CEST) and magnetic resonance spectroscopy (MRS) at 7T-MRI. Radiol Phys Technol, 12:46-54.","DOI":"10.1007\/s12194-018-0490-1"},{"key":"key-10.14336\/AD.2025.0619-147","doi-asserted-by":"crossref","unstructured":"Choi J, Dedeoglu A, Jenkins BG (2007). Application of MRS to mouse models of neurodegenerative illness. NMR Biomed, 20:216-37.","DOI":"10.1002\/nbm.1145"},{"key":"key-10.14336\/AD.2025.0619-148","doi-asserted-by":"crossref","unstructured":"De Graaf RA, Rothman DL, Behar KL (2011). State of the art direct13 C and indirect 1H\u2010[13 C] NMR spectroscopy in vivo. A practical guide. NMR Biomed, 24:958-72.","DOI":"10.1002\/nbm.1761"},{"key":"key-10.14336\/AD.2025.0619-149","doi-asserted-by":"crossref","unstructured":"Vaeggemose M, F Schulte R, Laustsen C (2021). Comprehensive Literature Review of Hyperpolarized Carbon-13 MRI: The Road to Clinical Application. Metabolites, 11:219.","DOI":"10.3390\/metabo11040219"},{"key":"key-10.14336\/AD.2025.0619-150","doi-asserted-by":"crossref","unstructured":"Bl\u00fcml S, Moreno\u2010Torres A, Ross BD (2001). [1\u201013 C] glucose MRS in chronic hepatic encephalopathy in man. Magn Reson Med, 45:981-93.","DOI":"10.1002\/mrm.1131"},{"key":"key-10.14336\/AD.2025.0619-151","doi-asserted-by":"crossref","unstructured":"Lin AP, Shic F, Enriquez C, Ross BD (2003). Reduced glutamate neurotransmission in patients with Alzheimer\u2019s disease?an in vivo 13C magnetic resonance spectroscopy study. Magn Reson Med, 16:29-42.","DOI":"10.1007\/s10334-003-0004-x"},{"key":"key-10.14336\/AD.2025.0619-152","doi-asserted-by":"crossref","unstructured":"Boumezbeur F, Mason GF, De Graaf RA, Behar KL, Cline GW, Shulman GI, et al (2010). Altered Brain Mitochondrial Metabolism in Healthy Aging as Assessed by in vivo Magnetic Resonance Spectroscopy. J Cereb Blood Flow Metab, 30:211-21.","DOI":"10.1038\/jcbfm.2009.197"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T04:12:30Z","timestamp":1751861550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2025.0619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":152,"URL":"https:\/\/doi.org\/10.14336\/ad.2025.0619","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}